Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?

Area of Science:

• Endocrinology
• Neurosurgery
• Oncology

Background:

• Pituitary tumors can cause hormonal imbalances and visual disturbances.
• Previous treatments like surgery and radiotherapy may not fully resolve symptoms.
• Pituitary-gonadal insufficiency is a common manifestation.

Purpose of the Study:

• To evaluate the efficacy of bromocriptine in patients with pituitary tumors.
• To assess bromocriptine's impact on hormone levels, tumor size, and visual function.

Main Methods:

• Twelve patients with pituitary tumors received bromocriptine (7.5-25 mg daily).
• Patients had prior treatments including surgery and/or radiotherapy.
• Follow-up duration ranged from 8 to 27 months (mean 15 months).

Main Results:

• Serum prolactin normalized in 7/9 patients with hyperprolactinemia.
• Serum growth hormone normalized in 2/2 acromegalic patients.
• Tumor size decreased with normalized hormone levels; vision improved in 5/6 patients.

Conclusions:

• Bromocriptine effectively corrects hormonal defects in pituitary tumors.
• It can improve visual field defects and reduce tumor size.
• Bromocriptine shows promise as a primary or adjunctive therapy for pituitary tumors.